Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2008
Business Overview: DaVita is a leading provider of dialysis services and related products. The company operates a large network of dialysis centers and provides ancillary services including pharmacy, vascular access, and disease management. As of April 30, 2008, the company had approximately 104.7 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Operating Revenues | $1,344,724 | $1,278,166 |
| Operating Income | $196,727 | $193,317 |
| Net Income | $86,934 | $76,582 |
| Diluted Earnings Per Share | $0.80 | $0.72 |
| Operating Cash Flow | $91,024 | $88,031 |
| Total Debt (Long-term + Current) | $3,705,435 | $3,707,318 |
| Cash and Cash Equivalents | $479,316 | $356,384 |
| Days Sales Outstanding (DSO) | 68 days | 66 days (Dec 2007) |
Margins: Operating margin was approximately 14.6% for Q1 2008. Patient care costs represented 69.2% of total operating revenues.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased by $66.6 million (5.2%) compared to Q1 2007. This was driven by a 6.0% increase in the number of treatments and growth in ancillary services, partially offset by a 2.8% decrease in average revenue per treatment due to lower pharmaceutical intensity and payor mix changes.
- Profitability: Net income increased by $10.4 million (13.5%) year-over-year. Operating income rose by $3.4 million.
- Expense Trends: Patient care costs increased $48.6 million year-over-year. General and administrative expenses increased $7.5 million, primarily due to higher labor costs and stock-based compensation. Debt expense decreased by $9.8 million compared to Q1 2007, attributable to principal prepayments and lower interest rates.
- Liquidity: Cash and cash equivalents increased by $32.3 million during the quarter. The company generated $91.0 million in operating cash flow.
Guidance, Outlook, and Risks
Guidance and Outlook
- 2008 Operating Income: Management projects full-year 2008 operating income in the range of $790 million to $850 million, noting it is more likely to be in the lower end of this range.
- Capital Expenditures: Expected to spend $110-$120 million on routine maintenance and IT, and $200-$220 million on new center development, relocations, and acquisitions.
- Operating Cash Flow: Projected to generate approximately $480 million to $530 million in 2008.
- Share Repurchases: The Board authorized an additional $143.5 million in repurchases on May 1, 2008, bringing the total outstanding authorization to $250 million.
Risks and Contingencies
- Government Investigations: The company is subject to multiple ongoing investigations by federal and state authorities (including the U.S. Attorney's Offices in Missouri, New York, and Texas, and the OIG) regarding EPO utilization, billing practices, and relationships with physicians. These could result in substantial penalties or exclusion from Medicare/Medicaid.
- Commercial Payor Rates: Approximately 36% of revenue comes from commercial payors, which generate nearly all profits. The company faces downward pressure on these rates due to consolidation among payors and aggressive negotiations.
- Medicare Payment Structure: Changes to the Medicare ESRD program, including potential "bundling" of pharmaceuticals and laboratory services into the composite rate, could significantly reduce reimbursement.
- Pharmaceutical Pricing and Utilization: Changes in clinical practices regarding EPO administration, FDA labeling changes, and pricing from sole supplier Amgen pose risks to revenue and margins.
- Debt Obligations: The company carries significant debt ($3.7 billion total principal). High indebtedness limits flexibility and exposes the company to interest rate fluctuations, though approximately 72% of total debt is economically fixed via swaps.
Investor Verification Checklist
- Regulatory Exposure: Verify the status of ongoing government investigations (Missouri, New York, Texas) and potential financial impact of penalties or recoupments.
- Commercial Rate Trends: Monitor the outcome of negotiations with commercial payors and the impact of rate reductions on the high-margin commercial segment.
- Medicare Bundling: Assess the likelihood and timing of CMS implementing a bundled payment system for ESRD services and its effect on pharmaceutical revenue.
- Debt Servicing: Confirm the company's ability to service $3.7 billion in debt given the projected operating cash flow and interest rate environment.
- Capital Allocation: Track the execution of the $250 million share repurchase program and capital expenditure plans for new center development.